
- POPULAR PRODUCTS
- Hepatocytes
- HepaRG™
- Silensomes™
- Skin
- FRACTIONS
- Homogenates
- S9 Fractions
- Cytosols
- Microsomes
- Silensomes™
REAGENTS AND PLATES - Reagents
- Plates

- Certificates of analysis
- FAQs
- Posters
- Publications
- User guides


Biopredic International is involved in several research projects with public and private organisations and is always keen to examine new scientific collaborations.
iLite - Innovations for Liver Tissue Engineering
The goals of this project are to build an external bioartificial liver, a liver-on-chip as well as a bioengineered liver. In the present project, bioconstruction of the liver will be performed by the assembly of building blocks –liver organoids, vascular networks and biliary networks- built separately and then integrated into a scaffold.
Predicting long-term toxic effects using computer models based on systems characterization of organotypic cultures.
NOTOX is one of the building block projects of the European research initiative SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) funded by EU-FP7 HEALTH programme and the European Cosmetics Association (Cosmetics Europe).
The total funding for the cluster projects is 50 million €. This initiative with six projects as building blocks aims at the common strategy “towards the replacement of current repeated dose systemic toxicity testing in human safety assessment”.
Real time in-vitro evaluation of carcinogenic potential of contaminants
The Genotrace project aims at bringing major technological innovations to develop a new micronucleus (MN) assay, that will allow the monitoring of both dynamically and in real time, the progression of chromosome damages and the signal of a genotoxic reporter on HepaRG™ cells.
The developed in-vitro MN assay will be adapted to a medium- to high-throughput straightforward readable assay, thanks to the implementation of high content screening imaging protocols and the development of an image analysis and classification-based pipeline.
The assay will bring new capacities to the classic MN assay and may lead to breakthroughs in the prevention and/or the diagnosis of exposure to genotoxicants present in the environment, food or future drug candidates.
Development of a Bioartificial liver therapy in acute liver failure
The BALANCE project takes up the challenge of realising the clinical development of a Bioartificial Liver (BAL) based on the human liver cell line HepaRG™ that for the first time enables increased survival in patients with severe liver failure. BALANCE is a 3 year project organised in 3 stages:
POPULAR PRODUCTS
CELLS
FRACTIONS